Autoimmune diseases gonna be defeated Scientists have designed and evaluated a prototype of a novel drug for arthritis

An international team of scientists led by the Lomonosov Moscow State University group made a significant step in creating a new type of drug for treatment of autoimmune diseases, such as rheumatoid arthritis and Crohn’s diseaase. The work was published in PNAShttp://www.pnas.org/cgi/doi/10.1073/pnas.1520175113

Scientists from Russia, Germany and Great Britain designed and developed a prototype of a new antibody-based drug for autoimmune diseases. The key role in this research was played by the scientists from MSU and Russian Academy of Sciences. The study was led by Sergei Nedospasov, the head of the Immunology Department of Biological faculty, MSU, and the Molecular Immunology Department, A.N. Belozersky Institute of Physic-Chemical Biology of MSU. He said that the experiments with mice provided a scientific basis for the new approach, allowing to selectively counteract deleterious functions of one of cytokines that may provoke serious diseases, while retaining its beneficial functions (such as control of tuberculosis).

In corpora sano

Each of us has a personal army of immune cells protecting their health: valorous macrophages, brave T-killers, vigilant T-helpers, teachable B-lymphocytes and other invisible (without a microscope) fighters.

The immune system is very complex and depends on a harmonious collaboration of all its parts. That is natural, as this system should defend us not only from the external threats (pathogenic bacteria, viruses, fungi, parasites), but also from the inside enemies (malfunctioning cells of our own body, ‘sabotaging’ its regular tasks).

Some of the immune cells may ‘overwork’ and instead of a protecting us they may turn in repressive mechanisms, resulting in autoimmune diseases.

Among such diseases are systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, Crohn’s disease (a chronic inflammatory bowel disease) and psoriasis. In the new study scientists learned how to selectively block overproduction of TNF — a protein, secreted by the immune cells for fighting diseases, but harmful when overproduced. TNF is blocked only on particular type of cells, and this that does not harm its other functions.

TNF: the good, the bad and the ugly

One of the immune system mediators, TNF (Tumornecrosisfactor), is a protein with a multiple functions. It can be secreted by macrophages, lymphocytes, neutrophils and other immune cells.

TNF and its related molecules belong to the cytokines. That is a group of small proteins, some of which can promote inflammation, some other counterbalance tumor formation, some are used to fight viral and bacterial infections, but all of them regulate the activity of the immune system.

Initially TN? was detected during experiments with blood serum of the mice that undergone a bacterial infection, or received bacterial components. It was found that transfer of such serum( orpure TNF protein) into tumor-bearing promotes tumor destruction, and that seemed to open a promising way for fighting cancer: you only need to launch the synthesis of large TNF quantities – and the malignant cells would start to die out. Apart from that, another ‘good’ function of that protein was uncovered: it helps protecting organism against TB.

But as many other multifunctional proteins, TNF has its dark side: it may turn to ‘the bad’ and promote serious diseases. Such ‘bad’ TNF needs to be neutralized.

Animmune uroboros

So, the hopes for cancer cure by TNF proved baseless: it turned out that this protein influences too may processes to be administered in a human body as a drug. Moreover, its physiologic function is quite different from tumor necrosis. That cytokine could be more properly named interleukin-x, but nobody wanted to rename TNF.

For the same reason the idea of a controlled overproduction of this cytokine in a human body was rejected. Furthermore, in order to treat some autoimmune diseases TNF should be inhibited. Such drugs are making about a half of the market for treatments of rheumatoid arthritis, psoriasis, Crohn’s disease and some other diseases (tens of billions of dollars per year!). However, dramatic side-effects may take place, for example, increased risk of malignancies and activation of a latent TB infection, because apart from ‘the bad’ TNF there is also ‘the good’ one in the body, that should better not be blocked.

Nothing to change but the chains: bispecific antibodies.

Each B-lymphocyte produces against a particular antigen only one antibody type consisting of two pairs of heavy and light chains. Though scientists learned long time ago to produce artificial, ‘chimeric’ antibodies that are able to stick to two proteins simultaneously with various Fab-fragments. Such antibodies are called bispecific. One of its advantages – a possibility to connect different cells using such an antibody – this was already used to produce effective cure for several kinds of tumors. In antibody bioengineering field, a particular type of antibodies from camel, lama or shark, which contain only heavy chains, can be used.

Scientists of the Immunology Department of Biological faculty, MSU, and Engelhardt Institute of Molecular Biology of the Russian Academy of Sciences designed, created and evaluated bispecific antibodies able to selectively inhibit TNF on a certain type of cells (macrophages), that produces mostly ‘the bad’ TNF in autoimmune diseases, without harming the function of ‘the good’ TNF.

‘This work lasted nearly ten years. The article describes only the tip of the iceberg,’ – comments the author of the study, Sergei Nedospasov. In our bi-specific antibodies one antigen was TNF itself, the other was a molecule from macrophage surface, called F4/80.

‘In experiments with mice a novel approach to anti-cytokine therapy was scientifically proven. This approach allows to neutralize the bad function of a molecule, retaining the good one. The main conclusion is that selective pharmacologic blockade of the immune mediator – cytokine – is possible on a particular type of producing cells,’ – says Sergei Nedospasov.

A new type of bispecific antibodies was called MYSTI (Myeloid-Specific TNF Inhibitor). They were designed using antibody ‘modules’ from camels and lamas.

For this study immunologists first created a novel mouse with its TNF gene replaced with a human counterpart (the so-called humanized mice) with a purpose to gain a more realistic model for further research. After treating such mice with bispecific antibodies TNF produced by macrophages was not secreted but remained attached to their surface, this was shown in macrophage culture prepared from humanized mice. Experiment was then extended to live humanized mice to prevent septic shock provoked by ‘the bad’ TNF from microphages. It turned out that at certain dose MYSTI protected mice from a lethal toxicity, while a control antibody did not.

‘Basedon these results pharmaceutical industry may design and test some brand-new drugs for treating autoimmune diseases,’ — Sergei Nedospasov optimistically prognoses.

But you don’t look sick? How broad categories like autoimmune impact patient experience

When your disease is hard to name and doesn’t have visible symptoms, it can be hard for others to understand that you are sick

You don't look sick
You don’t look sick

When your disease is hard to name and doesn’t have visible symptoms, it can be hard for others to understand that you are sick. And, when people don’t know much about your disease, it can be hard to explain it to family and friends.

This sentiment is particularly true for the some 50 million people in the United States living with autoimmune diseases, like lupus or multiple sclerosis (MS) — where the condition is chronic but achieving a specific diagnosis may take time, the diagnosis may change, symptoms may not be overtly apparent, and, in many cases, both a cause and a “cure” are unknown.

Patients with autoimmune diseases often have an illness experience riddled with symptom ambiguities and shifting diagnoses. A new Drexel University study found that one way patients and physicians can work through the difficulty and frustration of communicating about these conditions is to use both broad diagnostic terms, like “autoimmune disease,” as well as narrow ones, such as “lupus or MS.”

Kelly Joyce, PhD, a professor in Drexel’s College of Arts and Sciences and a member of the Center for Science, Technology & Society, studies the cultural dimensions of medicine. Her research investigates the experiences of people diagnosed with autoimmune illnesses. In analyzing how people live with autoimmune illnesses, Joyce and former Drexel graduate student Melanie Jeske found that the use of a broad category – like autoimmune – provides continuity, certainty and even community for patients who struggle to convey their often-inconsistent illness experiences with clinicians, family and friends.

Drawing on 45 in-depth interviews with people who live with autoimmune illnesses, Joyce’s research showed that both broad diagnostic classifications and narrow diagnostic classifications are integral to diagnostic work and illness experiences.

Talking About Illness:

Researchers found that participants, regardless of gender, age or specific disease diagnosis, tended to use the broad category “autoimmune” in addition to a specific diagnosis, like Celiac disease or Rheumatoid arthritis, to talk about their health.

Some of the reasons they used the terminology were to describe what’s happening in their bodies, and to make it easier to provide continuity, even when there was a change in their specific diagnosis.

“Although friends and families may not understand the precise mechanisms of Lupus or Rheumatoid arthritis, for example, they could understand the general autoimmune process in which the body’s immune systems attacks healthy tissue and cells,” Joyce said.

The broad term also simplified the process of talking about the disease to friends and family, even as the specific diagnosis might change over time.

“Use of the category ‘autoimmune’ meant participants did not have to put their lives on hold even as aspects of their specific diagnosis changed from ulcerative colitis to Crohn’s disease, from lupus to mixed connective tissue disease (MCT), from one type of MS or lupus to another type of MS or lupus, and from having MS to not having MS to having MS,” said Joyce. “Autoimmune, although an umbrella or broad category, is productive for those experiencing illness, lending legitimacy to the symptoms that a person will experience.”

It can also help to distinguish their affliction from others that are more stigmatized. One specific example of this was that participants who live with type 1 diabetes — which is an autoimmune disease — who use the broad terminology to distinguish their illness from type 2 diabetes — a chronic condition caused by the body’s inability to metabolize sugar — as a way avoiding the stigma and blame often associated with the latter.

Finding Community:

Because people can experience the same autoimmune disease differently, participants noted that using “autoimmune” allows them to see similarities between themselves and others– creating a sense of community and shared experience.

“Many participants in our study stressed the heterogeneity of autoimmune illnesses, often saying things like ‘My MS is not like her MS,’ or ‘No two people are alike,'” Joyce said. “While most participants knew others, who shared their specific diagnosis, it did not mean that their experience of symptoms, their triggers for symptoms, or their responses to particular treatments were similar.”

Raising Awareness:

Research has shown that people who are ill can benefit from social support when their disease is widely recognized. For example, there is often an outpouring of support during the various cancer and disease awareness months and efforts – both broadly in society and at an individual level. This unifying support can be difficult for illnesses like autoimmune disease that is not as well understood in society.

The researchers suggest that recognizing that autoimmune can be a range of diseases and disorders — similar to the way we think about the autism spectrum — could aid our collective understanding of these diseases and support for those who are suffering from it.

Why Broad Categories are Important:

More than 80 illnesses are considered to be autoimmune or autoimmune-related. Though the illnesses under the umbrella vary widely, the common thread is an immune response that attacks healthy cells, tissue and/or organs. The study suggests that the label autoimmune provides, at minimum, some understanding and a scientific explanation as to what is happening to patients, though an exact diagnosis may be a moving target.

While this research focuses specifically on autoimmune illnesses, it does signal that broad and narrow categories may be important to medicine more generally.

“Within medicine, clinicians and researchers use the language of lumping and splitting to distinguish between two valuable diagnostic classification practices,” said Joyce. “The process of lumping creates broad categories and emphasizes connections. In contrast, splitting emphasizes the differences between illnesses – creating categories that tend to be narrow and more specialized, prioritizing difference rather than similarity.”

Sociologists study how clinical encounters and medical practice are social practices, that is, practices imbued with values, beliefs, and institutional and policy incentives. Yet, many sociologists who study diagnostic practices have yet to acknowledge the importance of broad categories in diagnostic work, according to Joyce.

“They focus on how clinicians and patients use narrow diagnostic labels, missing the importance of broad categories,” she said. “Sociologists who study how people live with illnesses tend to focus on life after a specific diagnosis, so they have also paid little attention to the importance of broad categories in medical practice.”

Now That We Know:

In light of her findings, Joyce suggests clinicians should consider presenting patients with both broad and narrow disease classifications when discussing autoimmune diagnoses initially and over time.

The use of the broad category may provide continuity and certainty in doctor-patient communications even as narrow disease diagnoses change or when symptoms do not map neatly into diagnostic tests or markers.

Some health care organizations are taking the lead and reorganizing the delivery of services in recognition of the changing diagnoses and, at times, unknowable, dimensions of autoimmune illnesses. As an example of this reorganization, West Penn Hospital in Pittsburgh, Pennsylvania opened the first institute dedicated to autoimmune illnesses in February 2018.

In the excitement over precision medicine, Joyce notes this study shows the importance of maintaining the use of broad categories in the experience and treatment of illness as well as using narrow diagnostic labels.


Multiple Sclerosis and Fibromyalgia – is there a connection?




Fibromyalgia and multiple sclerosis

Fibromyalgia and multiple sclerosis

As some readers will know my background was conducting market research with people who suffer from various medical conditions. The main ones were in fact diabetes, cancer, rheumatoid arthritis and multiple sclerosis.

It was only when we started working with a lot of social media in around 2006 that I became commented with members of the fibromyalgia community.




You might also aware that we run various communities on Facebook and Twitter where we encourage discussion on a whole range of subject which are important to people with various conditions.

Over the years there has been a number of questions which come up from time to time. One of which is the relation between multiple sclerosis and fibromyalgia. After all having more than one autoimmune condition is not uncommon.

Indeed one of our members posted this on our page MultipleSclerosisTalk a few days ago “Hi. I just had a quick question. I am currently diagnosed with Fibromyalgia but with this last relapse, I have noticed many new and worsening symptoms, and I’m worried it may be more related to MS. I have a appointment with a neurologist on Tuesday and I was wondering how I should approach this with him. I’m really sick on this because I feel like they don’t really listen to how you feel sometimes. Thank you for any advice.”

Firstly if you do have any advice for this reader please feel free to use the comments box below to share your ideas.

Secondly I’m wondering how common this situation actually is? So I thought it would be useful to run the following poll to see how our readers have been diagnosed in the past.

It would great if you could take part below.





 

Bonnie2405 I think fibro me CFs lupus Lyme and ms are all the same, like polio, some get it small some get it big. If ritbixin works, they may have a cure for all of it, the virus attacks the autoimmune system that goes into overdrive, ritbixin removes all B cells wipes long term memory and the mitochondria has to start building healthy cells all over again freshly removing the virus from our bodies. The drug will be ready within three years are u ready to start recommending it DR because patients are desperate and want to try it they are that desperate.
traceychace Hi my name is Tracey, I was diagnosed with fibro about 3years ago after suffering for many years before hand.
My Dad had MS, my Mom has always said that she thought that’s what I have more than fibro.
My neurologist said that I deffinatley don’t have ms as there is no connection & its not hereditary.
My health seems to be deteriorating quite quickly, does fibro usually deteriorate quickly?
emily89 My mom was diagnosed with ms in her 30’s & im 24 I was just diagnosed with fibromyalgia, my older sister also has fibromyalgia. All of our symptoms are similar the only difference is that in an mri my mom has visible plaque on her brain.
anarivera Hi my name is ana rivera and i have fibromyalgia and i just cant find thevright medication can someone please help !!
RebeccaRaeThomas Go in with a detailed history of all symptoms over time and voice your concerns. Be assertive in getting additional tests. Don’t let them dismiss your concerns.

Barb MacLeod – 1 year ago
Diagnosed with IDDM (Type 1 or Insulin Dependent Diabetes Mellitus) in 1984; Diagnosed with RRMS (Relapsing Remitting Multiple Sclerosis) in 2015. My sister has Type 2 Diabetes diagnosed in 2012. My mother has Fibromyalgia diagnosed in 2014. It is tough being female in our family ! 🙂

Ileana Peters – 2 years ago
I was diagnosed with MS in 2011. i have a cousin that has fibromyalgia. Our symptoms are very similar . Its crossed our minds, she might have been misdiagnosed.

Carole mellor – 3 years ago
I was diagnosed with MS in 2008 and just been diagnosed now with Fibromyalgia the symptoms are very similar

linda Barlow – 3 years ago
Iv just fibormyalgy it’s a very painful ms what symptoms for that.